Compare Mattel Inc (MAT) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mattel Inc vs TransMedics Group Inc — how do they compare? Mattel Inc trades at $14.67 (market cap $4.30B), while TransMedics Group Inc trades at $86.65 (market cap $3.10B). The key difference: Mattel Inc is the larger of the two by market cap, and TransMedics Group Inc is trading nearer its 52-week high, Mattel Inc nearer its low. Which is the better fit depends on your goals.
| MAT | TMDX | |
|---|---|---|
Market Cap | $4.30B | $3.10B |
Sector | Consumer Cyclical | Technology |
52-Week High | $22.16 | $150.42 |
52-Week Low | $13.05 | $61.99 |
Enterprise Value | $6.52B | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mattel (MAT) trades at $14.74, down 0.34% today, with a bullish technical signal from moving averages and oversold RSI levels. Recent Q2 2026 earnings missed estimates despite 10% revenue growth, reflecting margin pressure from higher costs. The company maintains solid profitability with a 7.78% net margin and attractive valuation at a P/E of 11.22. Cash flow turned negative in 2025 due to increased financing outflows, though operations remain cash-generative.
Outlook is mixed: analyst consensus leans buy (53%) with a $14 price target, but rising expenses and toy market volatility pose risks. The stock's appeal hinges on execution of its entertainment-driven growth strategy and cost management amid economic headwinds.
TransMedics Group (TMDX) trades at $86.43, down 2.24% amid recent earnings misses but maintains strong analyst support with a $99.57 consensus target. The stock shows bullish technical signals with support at $84-87, though RSI levels suggest overbought conditions. Fundamentally, the company demonstrates robust profitability with 58.69% gross margins and 22.69% net income margins, despite recent quarterly earnings falling short of expectations.
Investment outlook remains positive given strong institutional backing and growth potential in organ transplant technology, though risks include ongoing fiduciary investigations and margin pressure from increased operating costs. The stock offers 15% upside to consensus targets but requires monitoring of Q3 earnings performance and legal developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mattel Inc
Mattel markets toy products that are sold to its wholesale customers and direct to retail consumers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, handheld and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Just over half of its net sales are in North America, while the remainder stem from international markets.
Read more on MAT →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
